1. Home
  2. Products
  3. Customized ADCs
  4. ACVR2B
  5. Anti-ACVR2B (Bimagrumab)-MC-MMAF ADC

Anti-ACVR2B (Bimagrumab)-MC-MMAF ADC (CAT#: ADC-W-652)

This ADC product is comprised of an anti-ACVR2B monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.

  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Name
  • ACVR2B
  • Alternative Names
  • ACVR2B; activin A receptor, type IIB; activin receptor type-2B; ActR IIB; HTX4; ACTRIIB; ActR-IIB;
  • Target Entrez Gene ID
  • 93
  • Overview
  • Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases. This gene encodes activin A type IIB receptor, which displays a 3- to 4-fold higher affinity for the ligand than activin A type II receptor.
  • Overview
  • Human Anti-ACVR2B IgG1-lambda antibody, Bimagrumab
  • Generic name
  • Bimagrumab
  • Host animal
  • Human
  • Species Reactivity
  • Human
  • Name
  • MC (maleimidocaproyl)
  • Description
  • Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
  • Name
  • MMAF
  • Description
  • Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Related Products

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform
Reviews
Development of Monoclonal Antibodies
Literature
CAMouse™-Fully Human Antibody Generation Platform
Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-652. Click the button above to contact us or submit your feedback about this product.

Quick Links

ADC Toxins
Drug-linker Complexes
Customized ADCs
Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload
CAT# Product Name Linker Payload
ADC-W-654 Anti-ACVR2B (Bimagrumab)-MC-Vc-PAB-SN38 ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) SN-38 (7-ethyl-10-hydroxycamptothecin)
ADC-W-655 Anti-ACVR2B (Bimagrumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-653 Anti-ACVR2B (Bimagrumab)-MC-Vc-PAB-MMAE ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) MMAE
ADC-W-651 Anti-ACVR2B (Bimagrumab)-SPDB-DM4 ADC SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-650 Anti-ACVR2B (Bimagrumab)-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
CAT# Product Name Linker Payload
ADC-W-2606 Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-115 Anti-CD33 (clone h2H12)-Mc-MMAF ADC Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-478 Anti-ENPP3-Mc-MMAF ADC Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-485 Anti-EphA2 (clone 1C1)-Mc-MMAF ADC Mc (maleimidocaproyl) MMAF (Monomethyl auristatin F)
ADC-W-2622 Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC MC (maleimidocaproyl) MMAF
CAT# Product Name Linker Payload
ADC-W-2591 Anti-EGFR (Cetuximab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2567 Anti-MUC16 (Sofituzumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2622 Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2550 Anti-CD74-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-2544 Anti-CD44 (Bivatuzumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF

Online Inquiry

Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.